<DOC>
	<DOCNO>NCT01649271</DOCNO>
	<brief_summary>The aim study determine Maximum Tolerated Dose ( MTD ) afatinib combination 3-weekly trastuzumab HER2 overexpressing cancer ass efficacy afatinib give MTD dosage , 3-weekly trastuzumab HER2 overexpressing metastatic breast cancer .</brief_summary>
	<brief_title>Phase I Trial Afatinib Trastuzumab HER2 Overexpressing Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients age 18 year old 2 . Patients cancer overexpressing HER2 Immunohistochemistry test ( IHC ) 3+ and/or IHC 2+ positive gene amplification FISH ( confirmation archive tissue need ) 3 . Written inform consent consistent ICHGCP guideline . 4 . Patients must eligible treatment trastuzumab . 5 . Patients must adequate organ function ( kidney , liver , bone marrow , cardiac ) 6 . Eastern Cooperative Oncology Group ( ECOG ) = 0 1 . 7 . Measurable disease accord RECIST 1.1 ( Phase Ib ) . Exclusion criterion : 1 . Active brain metastasis . 2 . Prior treatment erbB family target therapy within past four week start therapy concomitantly trial trastuzumab and/or lapatinib . 3 . Patients 2 line chemotherapy treatment metastatic breast cancer ( Phase Ib ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>